Showing results (141-150 of 180) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|June 25, 2017
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteriaLeena Gandhi, Sai-Hong Ignatius Ou, Alice T Shaw, et al.
The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
Carcinogenesis|January 26, 2013
DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classificationC Vanesa Díaz-García, Alba Agudo-López, Carlos Pérez, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistanceJon Zugazagoitia, Ana Gómez-Rueda, Eloisa Jantus-Lewintre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2011
A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancerEnrique Casado, Victor Moreno García, Jose Javier Sánchez, et al.
Cancer Discovery|March 6, 2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line OsimertinibZofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon, et al.
The Lancet. Oncology|August 19, 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysisScott J Antonia, Hossein Borghaei, Suresh S Ramalingam, et al.
Plos One|September 24, 2014
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistryEsther Conde, Ana Suárez-Gauthier, Amparo Benito, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced KRAS G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
The Lancet. Oncology|October 17, 2024
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.
Pageof 18